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Temporal Trends in Phthalate Exposures: Findings from the National Health
and Nutrition Examination Survey, 2001–2010
Ami R. Zota,1,2 Antonia M. Calafat,3 and Tracey J. Woodruff 2
1Department of Environmental and Occupational Health, School of Public Health and Health Services, George Washington University,
Washington, DC, USA; 2Program on Reproductive Health and the Environment, Department of Obstetrics, Gynecology, and Reproductive
Sciences, University of California, San Francisco, Oakland, California, USA; 3Division of Laboratory Sciences, National Center for
Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Background: Phthalates are ubiquitous environmental contaminants. Because of potential adverse
effects on human health, butylbenzyl phthalate [BBzP; metabolite, monobenzyl phthalate (MBzP)],
di-n-butyl phthalate [DnBP; metabolite, mono-n-butyl phthalate (MnBP)], and di(2-ethylhexyl)
phthalate (DEHP) are being replaced by substitutes including other phthalates; however, little is
known about consequent trends in population-level exposures.
Objective: We examined temporal trends in urinary concentrations of phthalate metabolites in the
general U.S. population and whether trends vary by sociodemographic characteristics.
Methods: We combined data on 11 phthalate metabolites for 11,071 participants from five cycles
of the National Health and Nutrition Examination Survey (2001–2010). Percent changes and least
square geometric means (LSGMs) were calculated from multivariate regression models.
Results: LSGM concentrations of monoethyl phthalate, MnBP, MBzP, and ∑DEHP metabolites
decreased between 2001–2002 and 2009–2010 [percent change (95% CI): –42% (–49, –34); –17%
(–23, –9); –32% (–39, –23) and –37% (–46, –26), respectively]. In contrast, LSGM concentrations of monoisobutyl phthalate, mono(3-carboxypropyl) phthalate (MCPP), monocarboxyoctyl
phthalate, and monocarboxynonyl phthalate (MCNP) increased over the study period [percent
change (95% CI): 206% (178, 236); 25% (8, 45); 149% (102, 207); and 15% (1, 30), respectively].
Trends varied by subpopulations for certain phthalates. For example, LSGM concentrations of
∑DEHP metabolites, MCPP, and MCNP were higher in children than adults, but the gap between
groups narrowed over time (pinteraction < 0.01).
Conclusions: Exposure of the U.S. population to phthalates has changed in the last decade. Data
gaps make it difficult to explain trends, but legislative activity and advocacy campaigns by non
governmental organizations may play a role in changing trends.
citation: Zota AR, Calafat AM, Woodruff TJ. 2014. Temporal trends in phthalate exposures:
findings from the National Health and Nutrition Examination Survey, 2001–2010. Environ Health
Perspect 122:235–241; http://dx.doi.org/10.1289/ehp.1306681

Introduction
Phthalate acid esters, also known as
phthalates, are the predominant type of plasti
cizer used around the world. Low-molecularweight phthalates, such as diethyl phthalate
(DEP), di-n-butyl phthalate (DnBP),
and diisobutyl phthalate (DiBP), are used in
personal care products, solvents, adhesives,
and medications [Kelley et al. 2012; Koniecki
et al. 2011; U.S. Environmental Protection
Agency (EPA) 2012]. High-molecular-weight
phthalates, such as butylbenzyl phthalate
(BBzP), di(2-ethylhexyl) phthalate (DEHP),
diisononyl phthalate (DiNP), and diisodecyl
phthalate (DiDP), are primarily used as plasti
cizers in polyvinyl chloride (PVC) applications found in building materials, cables and
wires, toys, and food packaging (Schecter
et al. 2013; Stringer et al. 2000; U.S. EPA
2012) (Table 1).
Phthalates are not chemically bound
to products and are therefore released into
the environment where they may enter the
human body via ingestion, inhalation, and
dermal absorption (Meeker et al. 2009).
Urinary metabolites of DEP, DnBP, BBzP,
and DEHP have been widely detected in the
U.S. population since 1999–2000, when
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phthalate metabolites were first systematically quantified in the National Health and
Nutrition Examination Survey (NHANES)
[Centers for Disease Control and Prevention
(CDC) 2013; Silva et al. 2004; Woodruff
et al. 2011]. Higher concentrations of some
phthalate metabolites have been documented
in certain sociodemographic subpopulations, including children (Koch et al. 2004;
Wittassek et al. 2011), females (Silva et al.
2004; Trasande et al. 2013), nonw hite
populations (Kobrosly et al. 2012; Trasande
et al. 2013), and those of lower socioeconomic
status (Kobrosly et al. 2012).
In animal studies, phthalates exhibit
marked differences in toxicity depending
on their chemical structure and timing of
the exposure (Foster 2005; Gray et al. 2000;
Howdeshell et al. 2008; National Research
Council 2008; Parks et al. 2000). In utero
exposure to certain phthalates, including
BBzP, DnBP, and DEHP but not others (e.g.,
DEP), during the sexual differentiation period
of rat development leads to reproductive tract
malformations in androgen- and insulin-like 3
(INSL3)–dependent tissues (Barlow and Foster
2003; McKinnell et al. 2005; Wilson et al.
2004). Human epidemiologic studies have
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reported associations between exposure to
DnBP, BBzP, and some other phthalates and
adverse male reproductive outcomes, including
reduced sperm quality, increased sperm DNA
damage, and altered male genital development
(Hauser et al. 2006, 2007; Meeker et al. 2009;
Swan et al. 2005). Other studies have reported
associations between gestational exposures to
phthalates, including DEP, DnBP, BBzP, and
DEHP, and outcomes suggesting impaired
behavioral development (Braun et al. 2013;
Engel et al. 2009; Swan et al. 2010; Whyatt
et al. 2012).
Given the scientific community and
public’s concern over phthalate toxicity, the
European Union (EU) has banned the use
of certain phthalates in toys, food-containing
materials, and cosmetics (EU 2004, 2005,
2007). The U.S. federal government enacted
legislation in 2008 that bans the use of DnBP,
BBzP, and DEHP in any amount > 0.1% in
child care articles including toys and placed
an interim restriction on DiNP, DiDP, and
di-n-octyl phthalate (DnOP) in toys that can
be put in a child’s mouth [Consumer Product
Safety Improvement Act (CPSIA) 2008; U.S.
EPA 2012]. Although phthalate content in
other products is not subject to legislative
oversight in the United States, environmental
and public health organizations have sought
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to reduce phthalate exposure by advocating
for the removal of phthalates from personal
care products and educating the public about
how to find potentially safer alternatives
(Campaign for Safe Cosmetics 2011).
Data on ingredient composition of con
sumer products are difficult to obtain because
reporting is not required by law, but there is
some evidence that the plasticizer market
is changing. DEHP, which has historically
been the most common phthalate plasticizer,
is increasingly being substituted with DiNP
and DiDP, and these two phthalates combined
account for 30–60% of the current plasticizer
market in the United States and the European
Union (European Chemicals Agency 2012).
Changes in reformulation and legislation
may have important implications for phthal
ates exposures, and subsequent health risks,
but until now, data were not available to
assess temporal trends in phthalate exposures.
Therefore, our study objective was to assess
temporal trends in exposure to phthalates by
analyzing changes in mean urinary concentra
tions of phthalate metabolites in the U.S. popu
lation between 2001 and 2010. In addition,
we sought to assess whether temporal trends in
urinary concentrations of phthalate metabolites
differ by age, sex, race/ethnicity, or household
income because these attributes have previously
been correlated with phthalate exposures.

Methods
Study population. We used data from the
2001–2002, 2003–2004, 2005–2006,
2007–2008, and 2009–2010 cycles of
NHANES, a nationally representative survey
and physical examination of the civilian, non
institutionalized U.S. population conducted
by the CDC. There were 13,288 participants

with urinary measurements of phthalate
metabolites and creatinine. We excluded
participants who did not self-identify as
non-Hispanic white, non-Hispanic black, or
Mexican American (n = 1,460) and/or were
missing information on household income
(n = 902), resulting in a final sample size of
11,071 study participants.
Phthalate metabolite measurements.
Phthalate metabolites are measured in approxi
mately one-third of NHANES participants.
Spot urine samples were collected in the
Mobile Examination Center and stored at
–20°C until shipped to the CDC’s National
Center for Environmental Health (Atlanta,
GA) for analysis. Concentrations of phthalate
metabolites were quantified using solid phase
extraction–high performance liquid chroma
tography–isotope dilution–tandem mass spec
trometry (CDC 2013). Laboratory files were
downloaded from the NHANES website in
October 2012 and included the needed correc
tions for impurities in some of the previously
used analytical standards (Langlois et al. 2012).
Fifteen phthalate metabolites have been
measured in NHANES, but not all metabo
lites were measured in all cycles. The limit of
detection (LOD) for a given metabolite often
varied by cycle. To facilitate analysis across
cycles, we assumed the maximal LOD for each
metabolite in our analysis, and substituted
values below the LOD with LOD divided by
the square root of 2 because this method is
used by the CDC (2013) and it produces rea
sonably nonbiased means and SDs (Hornung
and Reed 1990). This report includes the
11 metabolites detected in more than 50%
of the population in each cycle (LODs and
detection frequencies are available in the
Supplemental Material, Tables S1 and S2).

We calculated a summary metric for
DEHP metabolites (∑DEHP metabolites)
equal to the molar sum of mono(2-ethylhexyl)
phthalate (MEHP), mono(2-ethyl-5-hydroxy
hexyl) phthalate (MEHHP), and mono(2ethyl-5-oxohexyl) phthalate (MEOHP). [We
omitted mono(2-ethyl-5-carboxypentyl)
phthalate (MECPP) because it was not mea
sured in 2001–2002.] We divided the con
centrations of each metabolite by its molecular
weight (MW) to obtain the molar equivalent
(micromoles per liter) and then summed the
concentrations in micromoles per liter to
get total micromoles per liter of metabolites.
To facilitate comparison with other analytes
(Frederiksen et al. 2012; Wolff et al. 2010),
we multiplied total micromoles per liter of
metabolites by the average MW of the DEHP
metabolites (MW = 288 μg/μmol) resulting in
∑DEHP metabolites concentrations expressed
in nanograms per liter.
Statistical analysis. Analyses were con
ducted in SUDAAN, version 10.0 (Research
Triangle Institute, Cary, NC). Because we
combined five survey cycles, we calculated
new sample weights for each participant
according to the NHANES analytical guide
lines (National Center for Health Statistics
2006) equal to one-fifth of the 2-year sample
weights provided in the NHANES laboratory
files. The degrees of freedom for our study
sample equaled 77 and was calculated by sub
tracting the number of clusters in the first
level of sampling (strata) from the number of
clusters (PSUs, or primary sampling units) in
the second level of sampling (National Center
for Health Statistics 2006). Based on our
degrees of freedom, we used a critical value of
±1.99 from the t distribution for the calcula
tion of all confidence intervals. All analyses

Table 1. Phthalates and urinary metabolites measured in the NHANES biomonitoring program.
Phthalate
Dimethyl phthalate
Diethyl phthalate
Di-n-butyl phthalate

Abbrev
DMP
DEP
DnBP

Level of restriction
in the U.S.a
—
—
++

MWb
194.2
222.2
278.4

Urinary metabolites
Monomethyl phthalate
Monoethyl phthalate
Mono-n-butyl phthalate

Abbrev
MMP
MEP
MnBP

Diisobutyl phthalate
Butylbenzyl phthalate

DiBP
BBzP

—
++

278.3
312.4

MiBP
MBzP

Dicyclohexyl phthalate
Di(2-ethylhexyl) phthalate

DCHP
DEHP

—
++

330.4
390.6

Di-n-octyl phthalate

DnOP

+

390.6

Diisononyl phthalate

DiNP

+

418.6

Diisodecyl phthalate

DiDP

+

446.4

Monoisobutyl phthalate
Monobenzyl phthalate
Monobutyl phthalate (minor)
Monocyclohexyl phthalate
Mono(2-ethylhexyl) phthalate
Mono(2-ethyl-5-hydroxyhexyl) phthalate
Mono(2-ethyl-5-oxohexyl) phthalate
Mono(2-ethyl-5-carboxypentyl) phthalate
Mono(3-carboxypropyl) phthalate
Monooctyl phthalate
Monoisononyl phthalate
Monocarboxyoctyl phthalate
Monocarboxynonyl phthalate

MCHP
MEHP
MEHHP
MEOHP
MECPP
MCPPn
MOP
MiNP
MCOP
MCNP

Common sources
Insect repellent, plastic bottles, foodc,d
Fragrance, cosmetics, medicationse,f,g
Cosmetics, medications, food packaging, food,
PVC applicationse,g,h,i,j,k
Cosmetics, food, food packaginge,f,h,i
PVC flooring, food, food packagingh,l
Food, food packaging h
PVC applications, toys, cosmetics, food, food
packaginge,f,h,i,j,k,m
PVC applications, food, food packagingh,i,j
PVC applications, toys, flooring, wall coveringj,m,o
PVC applications, toys, wire and cables, flooringj,m,o

Abbreviations: —, no use restrictions; +, moderate use restrictions; ++, most use restrictions; abbrev, abbreviation.
aIndicates degree of risk management activities by federal and state governments in the United States (U.S. EPA 2012). b We classified DMP, DEP, DnBP, and DiBP as low-molecularweight phthalates, and BBzP, DCHP, DEHP, DnOP, DiNP, and DiDP high-molecular-weight phthalates. c Karunamoorthi and Sabesan (2010). dAl-Saleh et al. (2011). eKoniecki et al. (2011).
f Dodson et al. (2012). g Kelley et al. (2012). h Fierens et al. (2012). iSchecter et al. (2013). j Kawakami et al. (2011). kCirillo et al. (2013). l Kavlock et al. (2002). m Stringer et al. (2000). MCPP is
also a nonspecific metabolite of several high-molecular-weight phthalates. oEuropean Chemicals Agency (2012).
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> 3 (n = 3,828)]. This is a descriptive analysis, thus results for individual phthalates are
not corrected for multiple comparisons. A
(two-sided) p-value < 0.05 was considered
statistically significant.

Results
Concentrations of monobenzyl phthalate
(MBzP), mono-n-butyl phthalate (MnBP),
and monoethyl phthalate (MEP), metabolites
of BBzP, DnBP, and DEP, respectively, were
detected in at least 98% of participants in each
cycle. The detection frequency of monoiso
butyl phthalate (MiBP), a metabolite of DiBP,
increased monotonically from 72% in 2001–
2002 to 96% in 2009–2010. Concentrations
of MEOHP, mono(3-carboxypropyl) phthalate (MCPP), monocarboxyoctyl phthalate (MCOP), monocarboxynonyl phthalate
(MCNP), oxidative metabolites of DEHP,
DnOP, DiNP, and DiDP, respectively,
were detected in more than 89% of participants. (see Supplemental Material, Table S2;
comparisons made using maximal LODs).
Concentrations of MEP, MnBP, MBzP,
and the DEHP metabolites were significantly
lower in 2009–2010 than in 2001–2002
(Figure 1; see also Supplemental Material,
Table S3). LSGM concentrations of MEP
declined monotonically between 2005

and 2010; compared with 2001–2002,
LSGM concentrations were 20% (95% CI:
–30, –9%) and 42% (95% CI: –49, –34%)
lower in 2007–2008 and 2009–2010,
respectively. LSGM concentrations of
MBzP also steadily declined over time with
the largest percent change [–32% (95% CI:
–39, –23%)] observed between 2001–2002
and 2009–2010. There were no significant
differences in LSGM concentrations of MnBP
between 2001 and 2008, but 2009–2010
LSGMs were 17% lower (95% CI: –23, –9%)
than those in 2001–2002. The temporal trend
for ∑DEHP metabolites was nonmonotonic;
LSGM concentrations of ∑DEHP metabolites
increased from 39.3 ng/mL (95% CI: 36.3,
42.5) in 2001–2002 to 45.4 ng/mL (95% CI:
41.4, 49.7) in 2005–2006 and then decreased
to 24.8 ng/mL (95% CI: 21.5, 28.5)
in 2009–2010.
Concentrations of MiBP, MCPP, MCOP,
and MCNP were highest in 2009–2010
compared with earlier study cycles (Figure 2;
see also Supplemental Material, Table S3).
LSGM concentrations of MiBP monotonically
increased over time and were 206% higher
(95% CI: 178, 236%) in 2009–2010 compared with 2001–2002. LSGM concentrations of MCOP also monotonically increased
over time and were 149% higher (95% CI:
21
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were adjusted for the nonrandom sampling
design and the sample population weights.
We used multivariable regression models
to assess the relationship between each phthalate metabolite concentration and time. For
this analysis, we modeled NHANES sampling cycles using four indicator terms, with
participants sampled in 2001–2002 as the
reference group. Next, we constructed our
“core” multivariable regression models where
the outcome was phthalate metabolite concentrations and the independent variables were
NHANES sampling cycle and urinary creati
nine concentrations (to account for urinary
dilution) (Barr et al. 2005). We natural log–
transformed phthalate metabolite and creatinine data before regression analysis to account
for their non-normal distributions. We examined residual diagnostics after transformation
to assess these assumptions and tried various
transformations of the data to assess the sensitivity of the conclusions to the assumptions of
normality and equal variances.
From these regression models, we estimated a) percent changes in phthalate
metabolite concentrations by NHANES
cycle as [exp(β) – 1] × 100% with 95% CIs
estimated as [exp(β ± 1.99 × SE) – 1] where
β and SE are the estimated regression coefficient and standard error, respectively; and
b) least squares geometric means (LSGMs)
of phthalate metabolites concentrations
by NHANES cycle as exp(least squares
means) with 95% CIs as exp(least squares
mean ± 1.99 × SE) where the least squares
means is the cycle-specific mean of phthalate
metabolite concentrations after adjusting for
covariates. Next, we examined whether associations between NHANES sampling cycle
and phthalate metabolites concentrations varied by age, sex, race/ethnicity, or household
income. We first added the four demographic
covariates to the “core” regression model
described above. We then modeled multiplicative interactions between NHANES cycle
and each demographic variable one at a time
by adding product terms to the model for
the interaction being evaluated, in addition
to lower-order terms and covariates. LSGMs
for subgroups presented in the main text
were calculated from the multivariable models with the multiplicative interaction terms.
Demographic variables were categorized as
follows: age [children (6–11 years; n = 1,568),
adolescents (12–19 years; n = 2,524), and
adults (≥ 20 years; n = 6,979)]; sex [male
(n = 5,524) and female (n = 5,547)]; race/
ethnicity [non-Hispanic white (n = 5,305),
non-Hispanic black (n = 2,951), and Mexican
American (n = 2,815)]; and poverty–income
ratio (PIR; the ratio of household income
to poverty threshold adjusted to family size
and inflation) [< 1 (i.e., beneath the poverty
threshold; n = 2,604), 1–3 (n = 4,639), and
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Figure 1. Association between phthalate metabolites and NHANES sampling cycle in the general U.S. population for (A) MEP (n = 11,071; parent phthalate = DEP) (p < 0.0001); (B) MnBP (n = 11,071; parent phthalate,
DnBP; p < 0.0001); (C) MBzP (n = 11,071; parent phthalate, BBzP; p < 0.0001); and (D) ∑DEHP metabolites
(n = 11,071; parent phthalate, DEHP; p < 0.0001). Models are adjusted for urinary creatinine. Data points represent LSGM and error bars represent 95% CIs. Corresponding numeric data are provided in Supplemental
Material, Table S3. p-Value for the overall comparison between groups assessed by the Wald Test.
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Figure 2. Association between phthalate metabolites and NHANES sampling cycle in the general U.S.
population for (A) MiBP (n = 11,071; parent phthalate, DiBP; p < 0.0001); (B) MCPP (n = 11,071; parent
phthalates, DnOP and a nonspecific metabolite of high-molecular-weight phthalates; p < 0.0001); (C) MCOP
(n = 6,375; parent phthalate, DiNP; p < 0.0001); and (D) MCNP (n = 6,375; parent phthalate, DiDP; p = 0.004).
Models are adjusted for urinary creatinine. Data points represent LSGM and error bars represent 95%
CIs. Corresponding numeric data are provided in Supplemental Material, Table S3. p-Value for the overall
comparison between groups assessed by the Wald Test.
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Figure 3. Association between phthalate metabolites and NHANES sampling cycle in the general U.S.
population by age for (A) MEP (pinteraction = 0.04), (B) ∑DEHP metabolites (pinteraction = 0.002), (C) MCPP
(pinteraction = 0.0004), and (D) MCNP (pinteraction = 0.009). Estimates are from linear regression models
of interactions between NHANES sampling cycles and age adjusted for urinary creatinine, sex, race/
ethnicity, and PIR. Data points represent LSGM and error bars represent 95% CIs. Corresponding numeric
data are provided in Supplemental Material, Table S4.
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102, 207%) in 2009–2010 compared with
2005–2006 (earliest cycle). For MCNP,
LSGM concentrations were 15% higher
(95% CI: 1, 30%) in 2009–2010 compared
with 2005–2006 (earliest cycle) although
LSGM concentrations in 2005–2006 and
2007–2008 were statistically similar. The trend
in LSGM concentrations of MCPP was non
monotonic with the lowest LSGM occurring
in 2005–2006.
Temporal trends varied by age for MEP,
∑DEHP metabolites, MCPP, and MCNP
(Figure 3; see also Supplemental Material,
Table S4). For MEP and ∑DEHP metabo
lites, all three age groups had significantly
lower concentrations in 2009–2010 compared
with 2001–2002 but children had some notable differences compared with that of adolescents and adults (pinteraction = 0.04 and 0.002
for MEP and ∑DEHP metabolites, respectively). Children had the lowest LSGM concentrations of MEP in all cycles with relatively
stable exposures between 2001 and 2008;
whereas LSGM concentrations of MEP in
both adolescents and adults steadily declined
after 2005–2006. For ∑DEHP metabolites,
children had higher LSGM concentrations
than adolescents and adults in all cycles but
the differences between age groups narrowed
over time. In addition, the temporal trend for
∑DEHP metabolites in adults and adolescents
was nonmonotonic with highest LSGM concentrations in 2005–2006. For MCPP, the
trend was non-monotonic for all three age
groups, but among adults only, there was a
statistically significant increase in LSGM concentrations between 2001–2002 and 2009–
2010 (pinteraction = 0.0004). Similarly, LSGM
concentrations of MCNP in 2009–2010
were higher than those in 2005–2006 (earliest cycle); whereas in children and adolescents, these metabolite concentrations were
statistically similar over the study period
(pinteraction = 0.009).
For MnBP and ∑DEHP metabolites,
both sexes had significantly lower LSGMs in
2009–2010 compared with 2001–2002, but
the percent decrease was greater in females
than males (p interaction = 0.03 and 0.0001,
respectively) (Figure 4; see also Supplemental
Material, Table S5). Trends also varied by
race/ethnicity and PIR for ∑DEHP metabolites (pinteraction = 0.006 and 0.01, respectively)
and by PIR for MCPP (pinteraction < 0.0001)
(Figure 5). For example, the association
between PIR and MCPP concentrations varied by cycle. In 2001–2002, participants with
the lowest income (PIR < 1) had the highest
LSGM concentrations of MCPP. However,
in 2009–2010, income was inversely associated with MCPP concentrations and those
with the highest income (PIR > 3) had a significantly higher LSGM of MCPP than those
with the lowest income.
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We observed pronounced changes in urinary concentrations of phthalate metabolites
among the U.S. population between 2001
and 2010; urinary metabolite concentrations
of DEP, DnBP, BBzP, and DEHP declined
approximately 20–50%, whereas urinary
metabolite concentrations of DiBP and DiNP
increased by > 100%. To our knowledge,
this is the first examination to date of temporal trends in phthalates exposures among a
large, nationally representative sample of the
U.S. population. Our findings are consistent
with those from a German biomonitoring
study that examined temporal trends over
two decades in a convenience sample of predominately university students (age range,
20–29 years) (Wittassek et al. 2007).
Signiﬁcant data gaps make it difﬁcult
to identify the underlying reasons for the
observed trends in phthalate exposure with
certainty. Although biomonitoring studies are
useful for documenting population exposures
to environmental chemicals, they are limited
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in their ability to identify the contribution of
specific sources to personal exposure. Another
data source that could provide insight on
our findings is chemical production data
available from the U.S. EPA (Chemical
Data Reporting; http://epa.gov/cdr/). The
data available for our study period suggest
relatively stable trends in production for
most phthalates (see Supplemental Material,
Table S6). However, it is difficult to assess
temporal trends in U.S. phthalate production
with this data because chemical production
by year is reported as a range (e.g., 100–
500 million pounds/year) and not available
on an annual basis but instead in 4- to 6‑year
intervals. In Germany, where more precise
data is readily available, researchers report
that a decline in production was accompanied
by a decline in exposure to DnBP and DEHP
(Wittassek et al. 2011).
As expected, we observed declines in
metabolites of those phthalates that have
been the focus of legislative activities, including bans on DnBP, BBzP, and DEHP in
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from linear regression models of interactions between NHANES sampling cycles and sex, adjusted for
urinary creatinine, age (continuous), race/ethnicity, and PIR. Data points represent LSGM and error bars
represent 95% CIs. Corresponding numeric data are provided in Supplemental Material, Table S5.
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children’s products. However, legislative
activity does not entirely explain the observed
trends. For example, among the phthalates
in the present study, we found the largest
reductions in metabolite concentrations of
DEP, a phthalate used in fragrances that is
neither regulated in the United States or the
European Union. In addition, metabolites of
DnBP, BBzP, and DEHP were still detected
in nearly all participants and the decline in
DnBP metabolite concentrations was modest.
The success of advocacy efforts by public
health and environmental organizations such
as the Campaign for Safe Cosmetics (2014)
may partly explain some of our findings. This
campaign began in 2002 with a landmark
report that documented widespread detection
of DEP, DnBP, BBzP, and DEHP in the
majority of beauty products tested (Houlihan
et al. 2002). Over the last decade, it has used
a multip rong strategy to reduce phthalate
exposures from cosmetics by increasing consumer awareness of phthalate toxicity, creating a market for phthalate-free products,
and pressuring the cosmetics industry to
disclose chemical ingredients in their products (Campaign for Safe Cosmetics 2011).
Although there are few data available on the
extent of product reformulation in the United
States, there is some evidence to suggest that
the campaign’s activities have been influential in changing industry practices. For example, there has been an increased consumer
demand for alternative products making it
the fastest growing sector of the cosmetics
market (Campaign for Safe Cosmetics 2011).
Since 2004, more than 1,000 companies have
pledged to remove chemicals of concern from
personal care products and increase trans
parency of chemical ingredients in their products (Campaign for Safe Cosmetics 2011).
In 2008, the coalition tested a subset of
products originally examined in 2002 and
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Figure 5. Association between phthalate metabolites and NHANES sampling cycle in the general U.S. population by race/ ethnicity for ∑DEHP metabolites
(A; pinteraction = 0.006) and by PIR for ∑DEHP metabolites (B; pinteraction = 0.01) and MCPP (C; pinteraction < 0.0001). Estimates in (A) are from linear regression models of
interactions between NHANES sampling cycles and race/ ethnicity adjusted for urinary creatinine, age (continuous), sex, and PIR. Estimates in (B) and (C) are
from linear regression models of interactions between NHANES sampling cycles and PIR adjusted for urinary creatinine, age (continuous), sex, and race/
ethnicity. Data points represent LSGM and error bars represent 95% CIs.
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found less frequent detection and lower concentrations of phthalates in most products
(Campaign for Safe Cosmetics 2008). Our
data suggest that reductions in DEP exposures have been the most pronounced, possibly because of changes in the formulation
or use of personal care products, which are an
important source of exposure to DEP (Duty
et al. 2005; Just et al. 2010; Koch et al. 2013;
Wormuth et al. 2006). Consistent with this
hypothesis, metabolites of DnBP and DEHP
declined less than DEP in NHANES over
the study period. Diet is considered to be a
principle route of DEHP exposure (Fromme
et al. 2007; Koch et al. 2013; Wormuth et al.
2006), and DnBP exposures are not readily explained by either personal care product
use or food-related sources (Duty et al. 2005;
Fromme et al. 2007; Just et al. 2010; Koch
et al. 2013). Future studies should examine
how concentrations of individual phthalates
in common exposure sources (such as building materials, cosmetics, and food) are changing over time. Moreover, future intervention
efforts should consider aggregate sources of
exposure if the goal is to reduce overall risk.
The rise in metabolite concentrations of
DiBP and some high-molecular-weight phthalates suggest that manufacturers may be using
them as substitutes for other phthalates even
though the U.S. EPA has expressed concern
about their use (U.S. EPA 2012), and there
is an interim restriction on DnOP, DiNP,
and DiDP in certain children’s toys (CPSIA
2008). DiBP is structurally similar to DnBP
and may be a substitute for DnBP (Wittassek
et al. 2007). DiNP and DiDP are replacing
DEHP as a plasticizer in the global market
(European Chemicals Agency 2012), including in the green or “safer alternatives” market
(Dodson et al. 2012). For example, Dodson
et al. (2012) measured chemical ingredients in
conventional and alternative consumer products purchased in 2007 and detected DiNP
in alternative products only. Similarly, they
detected DiBP but not DnBP in nail polish
samples. Toxicological studies suggest that
DiBP and DiNP may disrupt androgen signaling and act cumulatively with other phthalates to affect male reproductive end points
(National Research Council 2008). Although
epidemiologic evidence of these replacement
phthalates is limited, a recent cross-sectional
study of 623 Norwegian children (Bertelsen
et al. 2013) reported associations between current asthma and urinary metabolites of DiNP
and DiDP, but not with any of the other
phthalate metabolites. Given the likely increase
in human exposure to replacement phthalates,
further study on their adverse health effects in
epidemiologic studies is warranted.
Our findings also suggest that temporal
trends in phthalates exposure are not uniform
across the population and that subpopulations
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with the highest initial phthalates exposures
often experienced the greatest decline over
the study period. For example, we observed
a more rapid decline in DEP metabolite
concentrations in adults and adolescents
compared with children, possibly reflecting
differences in personal care product use. We
also found a greater decline in concentrations
of DnBP and DEHP metabolites among
females than males, potentially reflecting differences in exposure sources or behavior. For
example, a Swiss study of 1,215 participants
found that women have a higher risk perception of chemicals and a stronger preference for
natural food than men (Dickson-Spillmann
et al. 2011). For high-molecular-weight
phthalates such as DEHP and DiDP, metabolite concentrations were higher in children
than adults, but the gap between groups narrowed over time. These phthalates are commonly used in PVC applications including
toys, and the larger reductions among children
may reflect the legislative emphasis on limiting
phthalates in children’s toys.
There are several key strengths to our
study. NHANES provides an unparalleled
opportunity to document changes in environmental chemicals exposures because
each survey captures a large, nationally
representative sample of the general U.S.
population that is diverse with respect to
geography, age, race/ethnicity, and income.
The large and diverse sample allows for
statistically reliable a ssessment of trends in
demographic subgroups.
Our main study limitation is the crosssectional design of NHANES that inhibits
examination of longitudinal changes in
phthalates metabolite concentrations in the
same participants. Also, NHANES does not
measure phthalate metabolites in children
< 6 years of age. Our findings may not be generalizable to young children, who may experience different exposures to some phthalates
than older children as a result of their higher
food consumption related to body weight,
higher dust ingestion from their playing habits, and distinct mouthing behavior (Becker
et al. 2009; Wittassek et al. 2011); children
also possess different behaviors and physiology
than adults (U.S. EPA 2008). Additional biomonitoring studies in young children may be
warranted because of their potentially higher
susceptibility to the adverse effects of environmental stressors and because young children
are likely to be most impacted by regulations
limiting phthalate content in toys. There may
be false positives due to the large number of
models evaluated. However, all of our main
findings (presented in Figures 1 and 2) and
half of the interaction models would pass
Bonferroni correction for multiple testing.
Last, although the CDC conducted all phthalate metabolite measurements, modifications
volume

were made to the analytical methods between
cycles that may affect the frequency of detection of the measured metabolites. To account
for some of these differences, we applied the
same LOD to each cycle.

Conclusions
Our analysis of biomonitoring data from
a nationally representative sample suggests
that U.S. population exposure to phthalates
has changed in the last decade. Although
exposures to DnBP, BBzP, and DEHP have
declined, exposures to replacement phthalates such as DiNP and DiBP have increased.
The observed temporal trends are difficult
to explain because of significant data gaps,
but may at least partly reflect the effects of
legislative activity and the advocacy efforts
of nongovernmental organizations on consumer behavior and the use of phthalates in
consumer products.
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